IMPORTANCE Synaptic loss is well established as the major structural correlate of cognitive impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could accelerate the development of disease-modifying treatments for AD. Synaptic vesicle glycoprotein 2A is an essential vesicle membrane protein expressed in virtually all synapses and could serve as a suitable target for synaptic density. CONCLUSIONS AND RELEVANCE To our knowledge, this is the first study to investigate synaptic density in vivo in AD using 11 C-UCB-J-PET imaging. This approach may provide a direct measure of synaptic density, and it therefore holds promise as an in vivo biomarker for AD and as an outcome measure for trials of disease-modifying therapies, particularly those targeted at the preservation and restoration of synapses.
A lzheimer disease (AD) affects 5.5 million people in the United States, and that number is expected to double by 2050 if no cure is identified. 1 From a diagnostic perspective, AD is increasingly viewed along a continuum from preclinical AD to mild cognitive impairment (MCI) to AD dementia. 2 The clinical features of AD are coupled to a distinct pathology, including β-amyloid plaques, neurofibrillary tangles, and synaptic loss. 3 Synapses are crucial for cognitive function, and synaptic loss is a robust and consistent pathology in AD. 4, 5 Cognitive impairment in AD is closely correlated with synaptic loss in the association cortex and limbic system. 6, 7 Synaptic damage associated with toxic β-amyloid oligomers is observed in the earliest clinical stages of AD, 8 with patients with MCI demonstrating a loss of synapses and synaptic proteins. 4, [9] [10] [11] [12] [13] Thus the ability to assess synaptic density in vivo would greatly enhance clinical research in AD and would specifically provide a valuable biomarker outcome for therapeutic trials. Positron emission tomography (PET) imaging is widely used in AD studies to measure glucose metabolism (fluorine 18-fluorodeoxyglucose [ 18 F-FDG]), β-amyloid, and neurofibrillary tangles.
14 Clinically,
18
F-FDG-PET imaging is used to differentiate AD from frontotemporal dementia and to track neuronal or synaptic activity as a surrogate biomarker of disease progression. 15 However,
F-FDG is not a direct biomarker of synaptic density, and test results may be confounded by sensory stimulation, medications, and blood glucose level. [16] [17] [18] [19] Inadequate fasting can result in false-positive results in AD scans. 17, 18 For this reason, new molecular targets for PET imaging are needed to specifically monitor synaptic density. Synaptic vesicle glycoprotein 2 (SV2) is an essential vesicle membrane protein and could be a suitable target. One of its isoforms, SV2A, is ubiquitously expressed in virtually all synapses. [20] [21] [22] Hence, SV2A-PET imaging could provide a highly useful indicator of synaptic density in AD and other neuropsychiatric disorders.
As described in our recent publications, [23] [24] [25] ((R)-1-((3-( 11 Cmethyl-11 C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one), more commonly known as 11 C-UCB-J, has demonstrated excellent characteristics for quantitative SV2A imaging in vivo in both nonhuman primates and humans, with excellent test-retest reproducibility. 25 Excellent correlations were also found among in vivo SV2A-PET measures, in vitro protein expression of SV2A and synaptophysin, a widely used presynaptic marker for synaptic density, and in vitro SV2A binding data in nonhuman primate brain homogenates. 24 Here we report what is, to our knowledge, the first study of in vivo SV2A-PET imaging for quantitative assessment of synaptic density in AD using 11 C-UCB-J and high-resolution PET. We hypothesized a reduction in hippocampal binding based on early degeneration of entorhinal cortical cell projections to the hippocampus (via the perforant path) 26, 27 and hippocampal SV2A reductions observed in postmortem studies of individuals with AD. 28 
Methods

Study Design and Participants
Potentially eligible participants who either had amnestic MCI or mild AD dementia or were cognitively normal and were aged between 55 and 90 years old underwent a screening diagnostic evaluation to ensure eligibility. Participants with AD dementia were required to meet diagnostic criteria for probable dementia because of AD according to the National Institute on Aging-Alzheimer Association 29 and have a Clini- C-PiB cerebral-to-cerebellar distribution volume ratio of 1.40 or more in at least 1 AD-affected region of interest (ROI). 31 Consequently, 1 participant with dementia devoid of β-amyloid accumulation and 1 participant who was cognitively normal with positive β-amyloid accumulation were excluded from the study. The study protocol was approved by the Human Investigation Committee and Radiation Safety Committee at Yale University. All participants provided written informed consent prior to participating in the study. previously described procedures. 25 All participants also received T1-weighted magnetic resonance images (MRIs) on a 3-T whole-body scanner (Trio; Siemens) for coregistration with the PET images.
Quantitative Analysis
Kinetic analysis was performed voxel by voxel using the 1-tissue compartment (1TC) model 25 and the metabolite-corrected arterial plasma curve to generate a parametric image of distribution volume (V T ). Distribution volume (V T ) is the tissue-toplasma concentration ratio at equilibrium and reflects total uptake (specific plus nonspecific binding) and is independent of local blood flow change. Images of the delivery rate constant, K 1 , which is indicative of perfusion, were also produced. Multiple ROIs were applied to the parametric images using the combined transformations from template to PET space (eMethods in the Supplement). Binding potential (BP ND ), a measure of specific binding only, was calculated for each ROI, using the centrum semiovale as the reference region (BP ND =V TROI / V Treference − 1). We also applied the simplified reference tissue model 2 (SRTM2) 32 using the centrum semiovale as a reference region to estimate regional-specific binding (BP ND ) without use of the arterial input function (eMethods in the Supplement). To evaluate the contributions of atrophy to the PET outcome measures, we masked ROIs with a segmented MRI (gray matter mask) and performed partial volume correction (PVC) according to previously described procedures. 33 In addition to the primary ROI analysis, voxelwise analysis was performed on K 1 , V T , and BP ND images for comparison between AD and cognitively normal groups using Statistical Parametric Mapping version 12 (SPM12; Wellcome Trust Centre for Neuroimaging). We also performed MRI volumetric analysis of cortical and subcortical gray matter volumes between AD and cognitively normal groups using FreeSurfer version 6 (Massachusetts General Hospital).
34,35
Statistical Analysis
Statistical calculations were performed using SPSS version 24 (IBM) and PRISM version 7 (GraphPad). Comparison of mean total uptake (V T ) and specific binding (BP ND ) values in the hippocampus between AD and cognitively normal groups was performed with 2-tailed, unpaired t test with P < .05 as a threshold for significance. A linear mixed model was also used to explore 11 C-UCB-J binding in multiple regions (withinparticipant factor) between the cognitively normal and AD groups. Additional exploratory analyses examined the relationship between hippocampal-specific binding (BP ND ) and episodic memory (average of z scores for LMII and the Rey Auditory Verbal Learning Test) and global function (CDR sum of boxes [CDR-SB]) in the combined sample with Pearson correlation coefficients, 2-tailed, with P < .05 as a threshold for significance.
Results
Twenty-one participants, including 10 with amnestic MCI due to AD or mild AD dementia and 11 who were cognitively normal, completed the study between November 2015 and June 2017. One PiB-negative participant with dementia and 1 PiB-positive participant who was cognitively normal were excluded. As shown in C-UCB-J binding was significantly reduced in the hippocampus of participants with AD compared with participants who were cognitively normal, suggesting loss of SV2A and synaptic density in this region ( Figure 1 ; Table 2 Table 2 ). The addition of age as a covariate in these statistical models did not improve the goodness of fit or alter the results.
An exploratory analysis of multiple ROIs was performed using a linear mixed model and showed a significant diagnostic group-region interaction for both V T (F 11,187 =2. 6;P = .004) and BP ND (F 11,187 =2. 7;P = .003). This analysis suggested ad- (Table 2) . To better illustrate the regional reduction of SV2A in the brain, SPM analysis was performed with surface rendering of differences in V T and K 1 between participants with AD (n = 9) and participants who were cognitively normal (n = 8). Figure 2A shows a significant reduction of SV2A binding in the hippocampus of participants with AD. Figure 2B presents group differences in the delivery rate constant K 1 , which extend to the temporal lobe, parietal lobe, and posterior cingulate gyrus in addition to the hippocampus. Notably, the patterns of SV2A V T for synaptic density and K 1 differed in individual participants ( Figure 1 ; eFigure 2 in the Supplement). The region-ofinterest analysis of K 1 (eTable 1 in the Supplement) did not show statistically significant reductions in temporal or parietal cortices, likely attributable to a diluted effect in larger ROIs. Notably, the pattern of regional K 1 reduction in the participant with AD, reflecting reduced cerebral blood flow, was thus similar to that of hypometabolism in AD, as demonstrated by 18 F-FDG-PET scan.
Because arterial data were not available for 1 participant with AD and 3 participants who were cognitively normal, SRTM2 was used to analyze the entire cohort. The value of hippocampalspecific binding BP ND generated by this method was highly correlated with that obtained from the 1TC model with the arterial input function (R 2 = 0.95; P < .001; eFigure 1 in the Supplement). Using SRTM2 in the full cohort, hippocampal BP ND was reduced by 41% in participants with AD (n = 10) compared with participants who were cognitively normal (n = 11) ( 
Research Original Investigation
The exploratory reduction in SV2A binding in the entorhinal cortex ( Table 2 ). Therefore, the loss of hippocampal SV2A-specific BP ND in participants with AD was much greater than the degree of brain atrophy.
Pearson correlations were performed to assess the relationship between synaptic density estimated by SV2A binding and clinical assessments (Figure 3) . Statistically significant correlations were found between SRTM2-derived hippocampus BP ND and episodic memory (based on mean z scores from the LMII and Rey Auditory Verbal Learning Test; R = 0.56; P = .01) and SRTM2-derived hippocampus BP ND and the CDR-SB score (R = −0.61; P = .003). Notably, 2 participants with MCI had relatively high and outlying values for hippocampal BP ND .
Discussion
Synaptic loss in the association cortex and limbic system is a robust and consistent pathology in AD 4 and is closely correlated with cognitive impairment. 6, 7 However, until now, the assessment of synaptic density and the quantification of presynaptic proteins in AD could only be performed in postmortem brain tissues. The present study demonstrated, for the first time, that noninvasive PET imaging with 11 C-UCB-J is capable of measuring reductions in synaptic density in vivo in the hippocampus of individuals with amnestic MCI and mild AD dementia. This finding was established by ROI analysis and corroborated by an exploratory whole-brain, voxel-wise analysis. The potential applications of SV2A-PET imaging with 11 C-UCB-J as an in vivo biomarker in AD include the early detection of synaptic loss, the monitoring of disease progression, and the evaluation of synaptic rescue and recovery through therapeutic interventions. Considerable postmortem and brain biopsy research has been devoted to the characterization of synaptic loss in AD. Most of these studies have necessarily been conducted in patients with advanced dementia. 4 However, some postmortem work 9-11,13,36 has been performed in patients at the prodromal AD or MCI stages. Because these studies vary by stage of disease and the early-stage studies frequently involve single brain regions, we presently lack a cohesive map of regional synaptic loss in early-stage AD. Postmortem work has established rather unequivocally that the earliest significant degeneration in AD occurs in en- C-UCB-J-PET, as measured by BP ND (41%). Notably, the only study to our knowledge that measured SV2A (and synaptophysin) in postmortem brain samples of individuals with AD also revealed reductions in the hippocampus. 28 The fact that our exploratory analysis of multiple brain regions found reduced SV2A binding in the entorhinal cortex is not unexpected, because degenerating entorhinal cortical cells also have local projections. However, the reduced SV2A binding in the entorhinal cortex may reflect the profound early atrophy in this region, 26 as this reduction, unlike those in the hippocampus, was almost identical to the degree of volume loss (eTable 3 in the Supplement) and did not persist after PVC. This is consistent with a postmortem study of synaptic density in MCI that found no reductions in the entorhinal cortex. 13 On the other hand, the fact that this exploratory analysis did not reveal synaptic losses in other brain regions, including the association cortical regions, may be attributable to limited statistical power in this small and disproportionately early-stage sample. Some, 11, 12 but not all, 13,36 pathologic studies of association cortical regions in participants with MCI have shown synaptic reductions. Postmortem samples of individuals with MCI are difficult to recruit, and the participants in the referenced studies are approximately 15 years older (with a mean age of 87 to 89 years [9] [10] [11] [12] 36 ) than those in the present study. Larger samples spanning more disease stages will be needed to provide a more comprehensive mapping of SV2A binding in patients with AD with 11 C-UCB-J-PET imaging. However, we expect that the largest losses in early-stage AD will continue to be observed in the hippocampus. As suggested by our data, possible SV2A decreases in the pulvinar nucleus may also be seen in early-stage AD, 37 perhaps reflecting the loss of axon terminals from the association cortices (eFigure 4 in the Supplement). However, this will require a larger cohort for confirmation. The results of our exploratory K 1 parametric imaging, which reflects blood flow, are very similar to the classic pattern of 18 F-FDG-PET in AD, 15 with decreased glucose metabolism or synaptic activity in the temporoparietal cortices. We propose that K 1 parametric imaging with 11 C-UCB-J may serve as a surrogate for brain perfusion, because similar concepts have been investigated previously using the early dynamic images with PET amyloid tracers. [38] [39] [40] We plan to compare K 1 parametric imaging from 11 C-UCB-J-PET scans with 18 F-FDG-PET imaging in the same participants to evaluate the usefulness of K 1 imaging in the clinical setting. This feature may yield useful information about perfusion or synaptic activity from K 1 mapping of early images and synaptic density from V T or BP ND parametric images within a single 11 C-UCB-J-PET study.
Limitations
Whether SV2A binding in AD is a direct measure of synaptic density is unclear. DeKosky and Scheff 7 reported that, in frontal cortical biopsy specimens of patients with AD, synaptic contact size increased and may have compensated for the numerical loss of synapses. Moreover, Snow et al 41 have
described an accumulation of SV2A in dystrophic neurites within the neuritic plaques, which might obscure synaptic loss in amyloid-rich regions.
In the combined samples of individuals who were cognitively normal and individuals with AD, we also observed statistically significant correlations between hippocampal SV2A specific binding (BP ND ) with both episodic memory score and global functioning (CDR-SB). The degree of association was only moderate, attributable in part to 2 participants with MCI who had outlying higher hippocampal SV2A binding. Interestingly, those 2 participants also had only minimal hippocampal atrophy on MRI scan. Larger samples are needed to clarify cognitive associations with regional SV2A binding in AD samples. Longitudinal within-participants analyses may be more powerful in this regard.
Conclusions
In conclusion, we have demonstrated, to our knowledge for the first time, reduced synaptic density in the hippocampus of living people with AD by PET imaging of SV2A with the radioligand 11 C-UCB-J. This method provides a direct measure of SV2A and synaptic density and therefore holds promise as a novel in vivo biomarker for AD and an outcome measure for trials of disease-modifying therapies, particularly those that target the preservation and restoration of synapses. Our novel SV2A-PET imaging for quantifying synaptic density in vivo could also provide a very useful and noninvasive tool for clinical and translational studies in a wide variety of neurologic and psychiatric disorders. The ROI for the centrum semiovale (white matter), to be used as a reference region, was based on the AAL region but was eroded by two voxels to minimize partial volume effects. The time-activity curve for the centrum semiovale was obtained by applying the eroded template ROI to PET space, and was subsequently smoothed to reduce estimation error in SRTM2 parametric imaging (see below).
Simplified Reference Tissue Model-2 (SRTM2) Analysis
SRTM2 can be used to estimate BP ND . This analysis requires a global value (clearance rate constant, k 2 , of the reference region), which was computed as follows: The parameter was fixed to a set of values which ranged from 0.010 to 0.080 min -1 with increment of 0.005. The total sum of squares from SRTM curve fitting of all brain voxels using each value was determined, and a quadratic curve was fitted to these sum of squares values. The k 2 ' value which provided the minimum sum of squares was chosen as the global value.
Statistical Parametric Mapping (SPM) Analysis
For voxel-wise analysis, T1 weighted images were spatially normalized by SPM12 (using SPM standard normalization in 1.5mm isotropic voxel size) and PET images were warped together with MRI. Warped PET images were smoothed by an 8-mm isotropic Gaussian kernel and masked to avoid the voxels in white matter or with low V T values. Then, we performed voxelwise 2-sample t-tests between AD and CN participants. The voxels were statistically thresholded at p < .05, with the threshold for cluster sizes >1000 voxels.
Region-based MRI Volumetric Analyses
Cortical reconstruction and volumetric segmentation were performed using FreeSurfer [version 6.0, http://surfer.nmr.mhg.harvard.edu/] (Fischl B Neuroimage 2012) 9 . Gray matter volume was
Regions analyzed included hippocampus, caudate nucleus, cerebellum, anterior cingulate gyrus, posterior cingulate gyrus, entorhinal cortex, frontal cortex, occipital cortex, parietal cortex, putamen, temporal cortex, and thalamus.
Linear Mixed Model Statistical Analysis
A linear mixed model was also used to explore 11 C-UCB-J binding in multiple regions (withinsubject factor) between the CN and AD groups. The best-fitting variance-covariance structure was determined by the Bayesian information criterion. The appropriateness of model selection was further confirmed by residual analysis. Post hoc comparisons between groups for each region were performed with two-tailed, unpaired student's t-tests that were not corrected for multiple comparisons. 
